Our current vaccine strategy against influenza virus is based on surface antigen-directed antibody responses and avoiding cellular immune responses.
The most current papers report on the development of immunoassays based on surface-immobilized antibodies (in most cases directly at the electrode) for binding of target biomarker.
In recent years, more and more new methods based on antibody or combined with antibody have been excavated, such as immunosensor [1, 90 92], molecularly imprinted technique [93, 94], surface plasma resonance sensing [95], and so on.
The current adenoviral taxonomy is based on antibody neutralisation assays, which are limited by antibody's reliance on surface accessible proteins in the capsid, and does not account for diversity in other viral proteins, as the above suggests for species B. This supports a taxonomic proposal based upon viral genetics rather than antibody neutralisation, as has previously been suggested13,48.
Efforts to improve the production of antibody manifolds based on this antibody are disclosed.
However, infected animals can still be identified based on OspF antibody values.
This enzyme immunoassay is based on monoclonal antibodies bound on the surface of the microwell strips to capture the antigen in stool specimens.
Two-site antibody binding assays have been developed, based on a surface immunological concept of hCG epitopes, that involve four distinct regions to which antibodies against hCG can bind simultaneously.
The quantitative comparison to the capture solely based on individual antibodies revealed that the multifunctional surfaces are most effective in capture efficiency across all CTC model cells tested, achieving up to 150-fold enhancement at up to 81% capture efficiency.
Earlier studies demonstrated the advantages of immunofluorescence assays, based on polyclonal antibodies to B. anthracis cell-surface antigens, for identifying B. anthracis isolates (8) and directly evaluating clinical specimens from infected guinea pigs (9).
